BIIB Biogen Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
21:00
Aug 26
Aug 26
Biogen has selected Veeva's Vault CRM, another major competitive win in the top-20 pharma segment, showcasing product trust and execution.
HIGH
10:56
Aug 13
Aug 13
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald.
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald, Roth/MKM, UBS, BofA, and Nomura issue multiple analyst upgrades and downgrades with various price target changes across a broad set of stocks.
17:15
Aug 04
Aug 04
Earnings beat, breakout above $218 possible.
Biogen beat top- and bottom-line expectations with earnings coming in 18% above consensus and forward guidance raised. The stock has knocked on $218 multiple times; a clean close above that level would confirm a breakout. Traders can use $190 as support, investors can anchor to the 200-day at $183.
HIGH
14:30
Jul 29
Jul 29
Biogen reports that sales from its newly acquired kidney and eye-disease drugs helped offset.
Biogen reports that sales from its newly acquired kidney and eye-disease drugs helped offset declining revenue from its multiple sclerosis medicines.
12:30
Jul 29
Jul 29
Management is clearly upbeat, projecting a return to sustainable revenue growth driven by the strong performance of its growth portfolio, the accretive Apellis acquisition, and a promising late-stage pipeline.
HIGH
11:42
Jul 29
Jul 29
Biogen reports second quarter 2026 revenue of 2.7 billion dollars with growth portfolio revenue.
Biogen reports second quarter 2026 revenue of 2.7 billion dollars with growth portfolio revenue up 24 percent year-over-year and GAAP diluted EPS of 66 cents.
11:35
Jul 29
Jul 29
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks.
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks including ABBV, KO, and F in a broad round of analyst upgrades.
10:14
Jul 29
Jul 29
Biogen reports Q2 2026 revenue and adjusted EPS well above estimates but cuts full-year.
Biogen reports Q2 2026 revenue and adjusted EPS well above estimates but cuts full-year adjusted EPS guidance to a range of 12 to 13 dollars from 14.25 to 15.25.
10:14
Jul 29
Jul 29
Biogen reports strong Q2 2026 earnings with revenue and EPS beating estimates but lowers its.
Biogen reports strong Q2 2026 earnings with revenue and EPS beating estimates but lowers its full-year adjusted EPS guidance.
10:14
Jul 29
Jul 29
Biogen reports Q2 2026 earnings with revenue and adjusted EPS beating estimates but lowers.
Biogen reports Q2 2026 earnings with revenue and adjusted EPS beating estimates but lowers full-year adjusted EPS guidance to reflect acquisition-related costs.
14:51
Jul 14
Jul 14
Biogen shares fell after additional data from a mid-stage study of its Alzheimer's drug.
Biogen shares fell after additional data from a mid-stage study of its Alzheimer's drug diranersen failed to show convincing evidence of benefit despite hints of improvement in some areas.
20:03
May 12
May 12
The tweet provides a detailed technical and cross-asset analysis highlighting overbought.
The tweet provides a detailed technical and cross-asset analysis highlighting overbought conditions, defensive rotation, and rising VIX that suggest a cautious or bearish outlook without explicitly stating the author's own directional trade.
12:00
Apr 29
Apr 29
Management's tone is optimistic, focusing on growth products and pipeline catalysts. The Apellis acquisition is projected to be accretive and drive EPS growth, alongside multiple data readouts, positioning the company for an inflection.
HIGH
12:00
Apr 21
Apr 21
Alzheimer's drugs from Biogen and Lilly are promising.
Anti-amyloid medicines from Biogen and Eli Lilly can break up plaques in the brain and, if given early, could dramatically slow cognitive decline. Data expected later in 2025 may show that early intervention could reduce decline by 40-50% or more.
MED
23:47
Apr 20
Apr 20
Biogen and Gilead are attractive.
Biogen looks attractive after an upgrade highlighting multiple revenue streams including Alzheimer's; Gilead is also liked in the biotech space.
MED
16:27
Feb 26
Feb 26
While Harvard's Allston development is failing, MIT's Kendall Square is described as the "most innovative square mile on the planet" with tenants like Biogen (BIIB) and Google (GOOGL) anchoring the area. In a crashing real estate market (70% vacancy elsewhere), capital and talent flight to quality ("flight to prime"). Companies located in the transit-accessible, thriving Kendall Square ecosystem are signaling resilience and superior positioning compared to competitors in "landlocked" developments. LONG these specific tenants as proxies for the "Quality" factor in the biotech/tech cluster. Broader sector downturns in Biotech or Tech could drag these names down regardless of their office location.
13:30
Feb 06
Feb 06
Management expresses confidence in the company's momentum, with growth products performing strongly and a robust pipeline, but guides for a top-line decline in 2026 as legacy MS products face generic competition.
HIGH
14:00
Feb 04
Feb 04
Vyalev (foslevodopa/foscarbidopa) is now expected to hit blockbuster status ($1B) in 2026, a year earlier than the prior >$1B peak guidance. — AbbVie's Parkinson's device franchise (Vyalev + Duopa) now has a peak sales potential of >$5B, competing directly with Biogen's approach in advanced Parkinson's.
MED
About BIIB Analyst Coverage
Buzzberg tracks BIIB (Biogen Inc.) across 10 sources. 4 bullish vs 0 bearish calls from 13 analysts. Sentiment: predominantly bullish (21%). 19 total trade ideas tracked. Latest voices: Paul Shawah, DeItaone, Josh Brown.